GSK CEO also-rans may get on board

Last week, the buzz about GlaxoSmithKline's CEO-presumptive Andrew Witty included worries that his internal competitors for the top slot would jump ship. Now Glaxo may sweeten the pot for those also-rans--by putting them on the board of directors.

The move would benefit Glaxo two ways: One, it might induce David Stout and Chris Viehbacher--both experienced execs--to stick around. Two, it would increase the proportion of execs to non-execs on the board; now, only three of the 14 directors are company types.

Meanwhile, there's talk in the executive suite about other ways to retain the two men. More responsibility, perhaps. More money, too. But as nothing has been decided yet, Glaxo's only official word is "no comment."

- check out the Financial Times report

Related Articles:
Just who is Glaxo's Andrew Witty? Report
GSK taps Witty as next CEO. Report
At GSK, a public race for the top spot. Report
GSK chief shrugs off growing criticism. Report
Riled investors look for big changes at GSK. Report

Read more on: GSK

Suggested Articles

Trump has said the coronavirus outbreak doesn't pose a major threat to the U.S., but the White House is weighing naming a "czar," Politico…

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.